Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amneal’s IPX-203 Increases ‘Good’ ON Time For Parkinson’s Patients

OFF Time Was Reduced With Longer-Acting Levodopa Product

Executive Summary

The proprietary carbidopa/levodopa formulation increased good ON time with fewer doses versus immediate-release levodopa. A post-hoc analysis also showed 1.55 hours more ON time per dose. 

You may also be interested in...



Amneal Spreads Bets On Generics Amid Focus On High-Barrier Opportunities

Amneal highlighted the benefits of a broad spread of generics and an increased shift towards complex products with high barriers to entry, as it reported generics sales growth in Q1 despite a tough operating environment for US generics.

Amneal Delivers On Biosimilars Ambitions With Neupogen Rival

Amneal has laid out its plans to enter the US biosimilars market after receiving FDA approval for its first biosimilar, a Neupogen rival known as Releuko (filgrastim-ayow) that was developed with partner Kashiv Biosciences. Amneal also intends to launch two more biosimilars soon, along with 20-30 generics launches planned in 2022. 

Amneal Aims To Be Among Top Five Biosimilars Players In US

Amneal’s president and co-CEO, Chirag Patel, has shared the company’s long-term plan of becoming one of the top biosimilars players in the US. The company is set to launch three biosimilars this year, while building its manufacturing capabilities and looking for opportunities and partnerships.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC144969

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel